NASDAQ:CCXI - ChemoCentryx Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$10.50 -0.52 (-4.72 %)
(As of 03/22/2019 01:04 AM ET)
Previous Close$11.02
Today's Range$10.50 - $10.99
52-Week Range$9.07 - $14.96
Volume149,100 shs
Average Volume369,393 shs
Market Capitalization$530.52 million
P/E Ratio-13.82
Dividend YieldN/A
Beta1.28
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Receive CCXI News and Ratings via Email

Sign-up to receive the latest news and ratings for CCXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$42.88 million
Book Value$0.29 per share

Profitability

Net Income$-37,970,000.00

Miscellaneous

EmployeesN/A
Market Cap$530.52 million
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable

ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

How were ChemoCentryx's earnings last quarter?

ChemoCentryx Inc (NASDAQ:CCXI) announced its earnings results on Monday, March, 11th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.06. The biopharmaceutical company had revenue of $9.33 million for the quarter, compared to analyst estimates of $9.54 million. ChemoCentryx had a negative net margin of 88.55% and a negative return on equity of 167.57%. View ChemoCentryx's Earnings History.

When is ChemoCentryx's next earnings date?

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for ChemoCentryx.

What price target have analysts set for CCXI?

8 brokerages have issued 12 month price objectives for ChemoCentryx's stock. Their forecasts range from $12.50 to $20.00. On average, they expect ChemoCentryx's share price to reach $17.5833 in the next twelve months. This suggests a possible upside of 67.5% from the stock's current price. View Analyst Price Targets for ChemoCentryx.

What is the consensus analysts' recommendation for ChemoCentryx?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 3 hold ratings, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ChemoCentryx.

Has ChemoCentryx been receiving favorable news coverage?

News stories about CCXI stock have been trending neutral this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ChemoCentryx earned a news impact score of 0.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the stock's share price in the near future.

Who are some of ChemoCentryx's key competitors?

What other stocks do shareholders of ChemoCentryx own?

Who are ChemoCentryx's key executives?

ChemoCentryx's management team includes the folowing people:
  • Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 60)
  • Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 56)
  • Dr. Rajinder Singh, Sr. VP of Research (Age 52)
  • Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 66)
  • Dr. Markus J. Cappel, Chief Bus. Officer & Treasurer (Age 58)

Who are ChemoCentryx's major shareholders?

ChemoCentryx's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.40%), Carmignac Gestion (2.42%), Acadian Asset Management LLC (1.62%), FMR LLC (1.28%), Dimensional Fund Advisors LP (1.25%) and Dimensional Fund Advisors LP (1.25%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Plc Glaxosmithkline, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.

Which major investors are selling ChemoCentryx stock?

CCXI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, American Century Companies Inc., Two Sigma Investments LP, Acadian Asset Management LLC, Carmignac Gestion, BlackRock Inc., Fosun International Ltd and GSA Capital Partners LLP. Company insiders that have sold ChemoCentryx company stock in the last year include Markus J Cappel, Plc Glaxosmithkline, Susan M Kanaya and Thomas J Schall. View Insider Buying and Selling for ChemoCentryx.

Which major investors are buying ChemoCentryx stock?

CCXI stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Geode Capital Management LLC, Geode Capital Management LLC, Alps Advisors Inc., SG Americas Securities LLC and BB&T Securities LLC. View Insider Buying and Selling for ChemoCentryx.

How do I buy shares of ChemoCentryx?

Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChemoCentryx's stock price today?

One share of CCXI stock can currently be purchased for approximately $10.50.

How big of a company is ChemoCentryx?

ChemoCentryx has a market capitalization of $530.52 million and generates $42.88 million in revenue each year. The biopharmaceutical company earns $-37,970,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

What is ChemoCentryx's official website?

The official website for ChemoCentryx is http://www.chemocentryx.com.

How can I contact ChemoCentryx?

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]


MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  206 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  403
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel